New Immunotherapy Combination Granted FDA Approval for Certain Adults with Multiple Myeloma
November 7th 2018Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma.
Read More